The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV ...
Total dividend declared for FY 2025 increased by 3% to $3.20 per share 16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months Pascal Soriot, Chief Executive Officer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results